413 results about "Immune activation" patented technology

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

The invention discloses a plant immune induced resistance protein PpAE4 and application thereof, and the protein can induce plant resistance and can be used as a plant immune activating factor to be applied to the field of prevention and treatment of plant diseases. The amino acid sequence of the protein is as shown in SEQ ID NO: 2. High-concentration protein can be obtained through expression of the engineering strain, the disease resistance of plants to soybean rust germs can be improved when the protein is used for treating the plants, and the protein is low in needed concentration, quick in effect taking and long in acting time. The PpAE4 provides a new way for improving plant disease resistance and preventing and treating plant diseases.

The invention belongs to the technical field of biology, and particularly relates to a composition for tumor targeted therapy, hydrogel and a preparation method and application thereof. The tumor targeted therapy composition provided by the invention comprises the aging tumor cells and the celecoxib, the immune activation function of the aging tumor cells is that STCs can effectively activate the maturation of dendritic cells and the immune function of T cells and NK cells, SASP of the STCs is regulated through the celecoxib, especially generation of prostaglandin E2 is inhibited, and the tumor targeted therapy effect is improved. And the combined use further enhances the anti-tumor immune effect.

The invention discloses a manganese-enriched albumin boron-containing nano preparation as well as a preparation method and application thereof, and belongs to the field of medicines and nano biological materials. According to the manganese-enriched albumin boron-containing nano preparation, albumin serves as a core carrier, phenylboronic acid derivatives are loaded through covalent or electrostatic interaction, then a manganese oxide layer is deposited on the surface in situ, and the prepared manganese-enriched albumin boron-containing nano preparation can remarkably increase the boron accumulation amount in tumor tissue; local and systemic immune response of tumors is promoted through the immune activation effect of manganese ions, so that the treatment effect of boron neutron capture therapy (BNCT) is remarkably improved. According to the invention, a phenylboronic acid derivative with tumor targeting is compounded with albumin, and manganese oxide is deposited in situ on the surface of the phenylboronic acid derivative, so that a multifunctional nano preparation with high boron delivery efficiency, immunological enhancement and magnetic resonance imaging functions is formed.

The invention provides a prawn immunity-enhanced fermented functional feed and a preparation method thereof. Belongs to the field of animal feed. The feed comprises a basal feed and a feed additive, the feed additive comprises the following components: lactobacillus plantarum fermentation liquor, passion flower flavone and an immature bitter orange extract. Three functional components including the lactobacillus plantarum fermentation liquor, the passion flower flavone and the immature bitter orange extract are fused, a synergistic interaction system is constructed through a definite proportion, and the immunity of prawns is remarkably improved; the sources and the content of effective components of the immature bitter orange extract and the lactobacillus plantarum fermentation liquor are strictly limited, and the controllable product quality is ensured; the preparation process of the feed is simple, the key growth stage of shrimp culture is accurately positioned, and a comprehensive solution integrating probiotic regulation and control, plant active ingredient immune activation and process feasibility is provided for healthy culture of prawns.

The invention provides a feed additive capable of improving immunity of pet cats as well as a preparation method and application of the feed additive, and belongs to the technical field of animal feed additives. The feed additive comprises probiotics and a traditional Chinese medicine extract, the probiotics comprise bifidobacterium animalis, combined lactobacillus salivarius and saccharomyces cerevisiae boulardii, and the traditional Chinese medicine extract comprises astragalus polysaccharide, curcumin and resveratrol. The probiotics directly enhance intestinal immunity through colonization resistance and metabolites, the traditional Chinese medicine components form internal and external dual defense through system immune activation, immunity-flora dual regulation is achieved, the probiotics and the traditional Chinese medicine extract form a symbiotic system of increasing the drug effect through bacteria and protecting the bacteria through drugs, and 1 + 1gt is achieved; and 2, the immunity improving effect is achieved.

Disclosed herein are immune cells expressing engineered cytokine receptor switches which, upon activation, can direct differentiation of the immune cells. The present disclosure further provides compositions and methods for transfecting, expanding, and activating these immune cells, including substrates which activate the engineered cytokine receptor switches disclosed herein.

The invention relates to an application of extracellular beta-glucan derived from aureobasidium melanogenum in preparation of a training immunity inducer. By establishing a mouse bone marrow derived macrophages (BMDMs) and zebra fish juvenile fish training immune activation evaluation model, the immunocompetence of extracellular beta-glucan (eBG) derived from aureobasidium melanogenum is evaluated, and it is found that the extracellular beta-glucan has a more remarkable training immune activation effect compared with beta-glucan (cBG) derived from cell walls, and the immunocompetence of the extracellular beta-glucan (eBG) derived from aureobasidium melanogenum is improved. It is proved that the extracellular beta-glucan (eBG) from the melanin-producing aureobasidium is an excellent training immunity inducer and has a good application prospect in the fields of feed addition of bred animals and disease immune prevention and control.

The invention belongs to the field of nutrient substance research, and particularly relates to a nutritional composition beneficial to improvement of neural behaviors and cognition. The nutritional composition provided by the invention comprises necessary active ingredients shown in the following (i) and (ii): (i) lactose-N-neotetraose, (ii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and (iii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine. The nutritional composition comprises lactose-N-neotetraose and 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine is 1: (0.010-2.0). The lactose-N-neotetraose and the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine can achieve a synergistic effect to improve filial generation repeated engraving behaviors caused by maternal immune activation, decrease of social behavior ability and decrease of anxiety state and memory and recognition ability.

The invention discloses an application of a training immune agonist in preparation of a drug for sensitizing radiotherapy treatment of tumors, and researches show that the training immune agonist significantly activates immune response of a body by promoting expression of inflammatory cytokines, enhancing phagocytic ability of macrophages, recruiting immune cells and amplifying an immune activation effect, so that the immune response of the body is enhanced. The sensitivity of tumor cells to radiotherapy is improved, and a dual mechanism of'radiotherapy sensitization-immune synergy 'is formed, so that the bottleneck of the traditional radiotherapy curative effect is broken through, the local control rate of radiotherapy is improved, and the recurrence risk is reduced. Experiments prove that the training immune agonist combined with radiotherapy has a remarkable treatment effect on various highly invasive tumors (such as brain glioma and lung cancer brain metastasis) and common malignant tumors (such as colon cancer and lung cancer), and shows wide applicability. The invention provides a new combined therapy direction for tumor treatment, is expected to improve the prognosis of patients, prolong the lifetime and improve the life quality, and has important clinical transformation value.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention belongs to the field of biological medicine and ultrasonic medicine, and provides a barium titanate (BTO) piezoelectric material-based ultrasonic responsive targeting nano system (BTO at BAL), which is used for matrix microenvironment remodeling and immunopotentiation of compact tumors such as pancreatic cancer and the like. According to the nanoparticles, oleic acid modified BTO is taken as a core, ROS responsive prodrug molecules containing a small molecule PD-L1 inhibitor BMS1166 and a nitric oxide donor (Arg) 9 are loaded on the surface, and specific targeting on pancreatic cancer cells is realized by combining a targeting peptide LFC131. Under ultrasonic excitation, BTO generates reactive oxygen species (ROS), on one hand, (Arg) 9 is oxidized to release NO, tumor matrix is degraded, tumor hardness is reduced, drug delivery efficiency is improved, and meanwhile, ROS and NO synergistically enhance tumor immunogenicity; on the other hand, the ROS breaks a thioketal bond to release BMS1166, PD-L1 expression is down-regulated, and immunosuppression is reversed. According to the present invention, the significant tumor inhibition and immune activation effects are represented in the animal model, and the clinical transformation potential is provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant oncolytic herpesvirus and application thereof. In order to solve the problems of insufficient replication efficiency, limited immune activation and the like of the existing oncolytic herpesvirus, the invention provides a recombinant oncolytic herpesvirus which contains a coding neurotoxic factor regulated by a tumor specific promoter or a gene related to replication and a gene segment for coding an immunomodulatory factor. Experiments prove that the recombinant oncolytic herpesvirus prepared by the invention has multiple advantages of high replication efficiency, strong tumor targeting, remarkable treatment effect on various tumors, high safety and the like, provides a brand new drug development thought and treatment choice for the field of tumor immunotherapy, and has important clinical application value and market prospect.

The invention discloses a nucleic acid tetrahedron nanostructure as well as a preparation method and application thereof. The nucleic acid tetrahedron nanostructure is composed of circRNA for coding an antigen, an ISD chain and two specific single-stranded DNA sequences, is simple and easy to prepare, can enter cells through cell membrane microfossa mediated endocytosis without the help of a transfection reagent, and is positioned to lysosome. The nanostructure is split to release circRNA coding antigen protein, and the circRNA coding antigen protein is delivered to APC and ISD chains in drainage lymph nodes (dLN) to activate cGAS-STING pathways, so that antigen presentation and immune activation are synergistically enhanced, T cells are efficiently and continuously activated, and the effect of tumor immunotherapy is achieved.

The invention relates to the field of traditional Chinese medicines, and discloses a preparation method and application of a pectic polysaccharide degradation product of an overground part of radix tetrastigme. The preparation method comprises the following steps: 1) extracting radix tetrastigme crude polysaccharide in the overground part of radix tetrastigme; 2) dialyzing the radix tetrastigme crude polysaccharide, and performing gradient elution through a cellulose column to obtain an eluent; (3) eluting with gel column water to obtain radix tetrastigme pectic polysaccharide; (4) carrying out enzymolysis on the radix tetrastigme pectic polysaccharide by using pectinase; and eluting with a gel column to obtain a degradation product of the tetrastigma hemsleyanum pectic polysaccharide. Compared with a product before enzymolysis, the pectic polysaccharide degradation product of the aboveground part of the radix tetrastigme, which is prepared by the method disclosed by the invention, has more advantages in the aspect of immune activation effect, and is beneficial to the development and application of the aboveground part of the radix tetrastigme in the fields of foods and medicines.

The invention discloses a method for wrapping stem cells by adopting programmable DNA (deoxyribonucleic acid) hydrogel and application of the method, under isothermal physiological conditions, three-dimensional DNA hydrogel is formed through a hybridization chain reaction of an initiation chain (I) and hairpin structure DNA to realize reversible wrapping and release of the stem cells. The hairpin structure DNA is formed by denaturation-renaturation treatment of at least two DNA monomer building blocks, and the mechanical rigidity of the hydrogel is realized by regulating and controlling the molar ratio of the initiation chain (I) to the total amount of the DNA monomer building blocks; the DNA hydrogel can reversibly wrap and release stem cells, and the wrapped stem cells can maintain activity and dryness and recover normal multiplication capacity after being released. According to the method disclosed by the invention, the activity and dryness of the stem cells are remarkably maintained, obvious immune activation is avoided, and the method provides a brand new tool for in-vitro culture and engineering application of the stem cells and has a wide application prospect.

The invention provides a PDCoV virus mRNA (messenger Ribonucleic Acid) vaccine capable of self-cleaving and expressing a plurality of virus structural proteins and a preparation method of the PDCoV virus mRNA vaccine, and the vaccine comprises mRNA for expressing S, M and N proteins of a PDCoV virus and LNP for encapsulating the mRNA, and the LNP is marked as SMN-mRNA-LNP. The invention provides a PDCoV mRNA vaccine strategy based on combination of S, M and N for the first time, the S, M and N structural proteins of the PDCoV are connected by using a self-cleavage peptide P2A, the S protein is subjected to double proline mutation, so that a single mRNA can express multiple PDCoV antigens, and a multi-level defense system is constructed by using the neutralizing antibody induction capability of the S protein, the immune regulation function of the M protein and the cellular immune activation characteristic of the N protein. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea is provided for development of broad-spectrum and efficient PDCoV vaccines, and a practical basis is provided for research and development of coronavirus multi-antigen mRNA vaccines.

The invention relates to a cationized manganese nano adjuvant as well as a preparation method and application thereof. The cationized manganese nano adjuvant comprises manganous-manganic oxide nano particles and cationized template molecules wrapping the surfaces of the manganous-manganic oxide nano particles, the cationization template molecule is a protein subjected to cationization modification treatment, or a protein fragment thereof, or a polypeptide fragment thereof. Precise regulation and control of surface charges and structures of the manganese nanoparticles are realized through a biomineralization technology, and the key problems of a traditional vaccine adjuvant in the aspects of antigen delivery, immune activation and biocompatibility are effectively solved. The cationized manganese nano adjuvant can efficiently adsorb various antigens to form a stable nano vaccine compound, and congenital immunity and adaptive immunity response of an organism can be remarkably activated; lymph nodes can be effectively targeted, the enrichment degree of antigens in the lymph nodes is improved, and the immune effect is further enhanced; meanwhile, the biotoxicity is low, and the stability is excellent.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

The application provides a PDCoV virus mRNA vaccine which can be self-cleaved and expresses multiple virus structure proteins and a preparation method thereof, the vaccine comprises mRNA for expressing PDCoV virus S, M and N proteins, and LNP for encapsulating the mRNA, denoted as SMN-mRNA-LNP. The application firstly proposes a PDCoV mRNA vaccine strategy based on S, M and N combination, connects three structure proteins of PDCoV S, M and N by using a self-cleaving peptide P2A, mutates the S protein with double proline, enables a single mRNA to express multiple PDCoV antigens, and utilizes the neutralizing antibody induction ability of the S protein, the immune regulation function of the M protein and the cell immune activation characteristics of the N protein to construct a multi-level defense system. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea for developing a broad-spectrum and high-efficiency PDCoV vaccine is provided, and practical basis for research and development of a coronavirus multi-antigen mRNA vaccine is provided.

The invention provides an allosteric nanogel adjuvant as well as a preparation method and application thereof, and belongs to the technical field of vaccines. The allosteric nanogel adjuvant comprises a self-assembly motif, a responsive site and an immunomodulatory peptide fragment, and the self-assembly motif is composed of 2-5 amino acids; the allosteric nanogel adjuvant has a structure as shown in a formula I, and is named as NTP5 for short; the allosteric nanogel adjuvant is self-assembled into nanoparticles, the nanoparticles are allosteric into a nanofiber structure through responsive broken bonds, nanogel is further formed, and the key problems of a traditional vaccine in the aspects of antigen delivery and immune activation are effectively solved. The nanogel adjuvant can efficiently load various antigens to form a stable nano vaccine, activate an immune microenvironment and provide more means and thoughts for vaccine development.

The invention discloses a protein capable of inducing a plant immune activation function and application of the protein in disease control, the gene sequence of the protein capable of inducing the plant immune activation function is shown as SEQ ID NO: 1, and the amino acid sequence of the protein is shown as SEQ ID NO: 2. According to the invention, a novel plant immune activator protein CgSsp16 secreted by colletotrichum gloeosporioides is identified, can be identified by plants, stimulates a plant immune response mechanism, triggers broad-spectrum resistance of host plants to various pathogens and improves disease resistance of various plants; the compound is expected to be developed into a novel biopesticide to be applied to green and sustainable production of agriculture.

The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.

The application provides a compound microbial agent for preventing and treating bacterial diseases of fruits and vegetables and a preparation method thereof, wherein the compound microbial agent comprises Brevibacillus brevis, Pseudomonas chlororaphis and Streptomyces; wherein the ratio of the viable bacterial count of the Brevibacillus brevis, the Pseudomonas chlororaphis and the Streptomyces is (1-3):(2-4):(1-2). The Brevibacillus brevis directly inhibits bacteria by secreting antibacterial peptides, the Pseudomonas chlororaphis competes for ecological niches through iron carriers, and the Streptomyces produces antibiotics, so that multiple strains form a "bacteriostasis-competition-immune activation" multiple mechanism, thereby achieving efficient prevention and treatment of bacterial diseases of fruits and vegetables.

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

Soluble gp120 (sgp120) is associated to HIV-1-induced immune dysfunction, such as chronic immune activation. However, the detection of sgp120 in biological fluids such as plasma, serum, cervicovaginal fluids, and cerebrospinal fluids is challenging. The present application relates to novel methods and kits for the detection of sgp120 in biological fluids. These methods and kits are based on the use of specific combinations of sgp120-binding molecules recognizing particular domains of sgp120, notably the N-terminal 8-stranded β-sandwich structure, the constant region 1 and 2 (C1-C2) portion, the bridging sheet of the Co-Receptor Binding Site (CoRBS), and / or the CD4-binding domain.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.